Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial Cyriel Y Ponsioen, E Joline de Groof , Emma J Eshuis , Tjibbe J Gardenbroek , Patrick M M Bossuyt, Ailsa Hart, Janindra Warusavitarne, Christianne J Buskens, Ad A van Bodegraven, Menno A Brink, Esther C J Consten, Bart A van Wagensveld, Marno C M Rijk, Rogier M P H Crolla, Casper G Noomen, Alexander P ..
Infliximab with Azathiopurine in Ulcerative Colitis Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Infliximab Azathiopurine combination therapy in ..
Infliximab with Azathiopurine (Crohn) Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease Jean Frédéric ..
Infliximab with Methotrexate (Crohn) Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in ..
Below are two abstracts and figures regarding the outcome in long term Vedolizumab use in Crohn or Colitis. Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol 2017;52:722–9. Objectives: Clinical ..
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri, Neil Chanchlani, Neel M Heerasing, Peter Hendy, SimengLin, Daniel R Gaya, J R Fraser Cummings, Christian P ..
Bruce E. Sands, William J. Sandborn, Gert Van Assche, Milan Lukas, Jing Xu, Alexandra James, Brihad Abhyankar, Karen Lasch, Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy, Inflammatory Bowel Diseases, Volume 23, Issue 1, 1 January 2017, Pages 97–106, https://doi.org/10.1097/MIB.0000000000000979 Background ..
Effects of Withdrawal of Immunomodulators or Biologic Agents IBD Withdrawal of IBD (Inflammatory Bowel Disease) therapy; for example anti-TNF. 50% or more of patients with IBD who cease/stop therapy have a disease relapse. The decision to withdraw a drug should be made for each individual based on patient preference, disease markers, consequences of relapse, safety, ..